Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction

Journal of Clinical Investigation

Volumn 116, Issue 6, 2006, Pages 1547-1560

  Perrino, Cinzia ^a   Naga Prasad, Sathyamangla V ^a   Mao, Lan ^a   Noma, Takahisa ^a   Yan, Zhen ^a   Kim, Hyung Suk ^b   Smithies, Oliver ^b   Rockman, Howard A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; STRESS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; BLOOD PRESSURE; BLOOD VESSELS; CARDIAC OUTPUT, LOW; CARDIOMEGALY; CELLS, CULTURED; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION REGULATION; HEART; HEMODYNAMIC PROCESSES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; METOPROLOL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; PHENOTYPE; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; STRESS;

EID: 33745185351     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI25397     Document Type: Article

References (54)

1. Meerson, F.Z. 1962. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ. Res. 10:250-258.
2. Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., and Castelli, W.P. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1561-1566.
3. Frey, N., Katus, H.A., Olson, E.N., and Hill, J.A. 2004. Hypertrophy of the heart: a new therapeutic target? Circulation. 109:1580-1589.
4. Esposito, G., et al. 2002. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 105:85-92.
5. Yusuf, S., et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145-153.
6. Devereux, R.B., et al. 2004. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292:2350-2356.
7. Gardin, J.M., and Lauer, M.S. 2004. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 292:2396-2398.
8. Badorff, C., et al. 2002. Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109:373-381. doi:10.1172/JCI200213779.
9. Brancaccio, M., et al. 2003. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9:68-75.
10. Hirota, H., et al. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 97:189-198.
11. Meguro, T., et al. 1999. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84:735-740.
12. Rogers, J.H., et al. 1999. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104:567-576.
13. Nienaber, J.J., et al. 2003. Inhibition of receptor-localized PI3K preserves cardiac β-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112:1067-1079. doi:10.1172/ JCI200318213.
14. Tachibana, H., Naga Prasad, S.V., Lefkowitz, R.J., Koch, W.J., and Rockman, H.A. 2005. Level of betaadrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation. 111:591-597.
15. McMullen, J.R., et al. 2003. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100:12355-12360.
16. Akimoto, T., Ribar, T.J., Williams, R.S., and Yan, Z. 2004. Skeletal muscle adaptation in response to voluntary running in Ca2+/calmodulin-dependent protein kinase IV-deficient mice. Am. J. Physiol. Cell Physiol. 287:C1311-C1319.
17. Rockman, H.A., et al. 1991. Segregation of atrialspecific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 88:8277-8281.
18. Rapacciuolo, A., et al. 2001. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload carcardiac hypertrophy. J. Am. Coll. Cardiol. 38:876-882.
19. Christensen, N.J., and Galbo, H. 1983. Sympathetic nervous activity during exercise. Annu. Rev. Physiol. 45:139-153.
20. Liang, C., Tuttle, R.R., Hood, W.B., Jr., and Gavras, H. 1979. Conditioning effects of chronic infusions of dobutamine. Comparison with exercise training. J. Clin. Invest. 64:613-619.
21. Lowes, B.D., et al. 1997. Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J. Clin. Invest. 100:2315-2324.
22. Nakao, K., Minobe, W., Roden, R., Bristow, M.R., and Leinwand, L.A. 1997. Myosin heavy chain gene expression in human heart failure. J. Clin. Invest. 100:2362-2370.
23. Cho, M.C., et al. 1999. Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J. Biol. Chem. 274:22251-22256.
24. Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. 2002. Seven-transmembrane- spanning receptors and heart function. Nature. 415:206-212.
25. Choi, D.J., Koch, W.J., Hunter, J.J., and Rockman, H.A. 1997. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J. Biol. Chem. 272:17223-17229.
26. Perrino, C., Naga Prasad, S.V., Patel, M., Wolf, M.J., and Rockman, H.A. 2005. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J. Am. Coll. Cardiol. 45:1862-1870.
27. Perrino, C., et al. 2005. Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation. 111:2579-2587.
28. Sadoshima, J., et al. 2002. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J. Clin. Invest. 110:271-279. doi:10.1172/JCI200214938.
29. Zhang, D., et al. 2000. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6:556-563.
30. Takaoka, H., Esposito, G., Mao, L., Suga, H., and Rockman, H.A. 2002. Heart size-independent analysis of myocardial function in murine pressure overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 282:H2190-H2197.
31. Sasayama, S., Franklin, D., and Ross, J., Jr. 1977. Hyperfunction with normal inotropic state of the hypertrophied left ventricle. Am. J. Physiol. 232:H418-H425.
32. Patrucco, E., et al. 2004. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell. 118:375-387.
33. Shiojima, I., et al. 2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115:2108-2118. doi:10.1172/JCI24682.
34. Lefkowitz, R.J., and Shenoy, S.K. 2005. Transduction of receptor signals by beta-arrestins. Science. 308:512-517.
35. Rajagopal, K., Lefkowitz, R.J., and Rockman, H.A. 2005. When 7 transmembrane receptors are not G protein-coupled receptors. J. Clin. Invest. 115:2971-2974. doi:10.1172/JCI26950.
36. Zou, Y., et al. 2004. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 6:499-506.
37. Miyata, S., Minobe, W., Bristow, M.R., and Leinwand, L.A. 2000. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86:386-390.
38. Lowes, B.D., et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346:1357-1365.
39. Dorn, G.W., II, and Force, T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 115:527-537. doi:10.1172/JCI200524178.
40. Bueno, O.F., et al. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:6341-6350.
41. Frederiksen, J.W., Weiss, J.L., and Weisfeldt, M.L. 1978. Time constant of isovolumic pressure fall: determinants in the working left ventricle. Am. J. Physiol. 235:H701-H706.
42. Gaasch, W.H., Blaustein, A.S., Andrias, C.W., Donahue, R.P., and Avitall, B. 1980. Myocardial relaxation. II. Hemodynamic determinants of rate of left ventricular isovolumic pressure decline. Am. J. Physiol. 239:H1-H6.
43. Crackower, M.A., et al. 2002. Regulation of myocardial contractility and cell size by distinct PI3KPTEN signaling pathways. Cell. 110:737-749.
44. Naga Prasad, S.V., Jayatilleke, A., Madamanchi, A., and Rockman, H.A. 2005. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat. Cell Biol. 7:785-796.
45. Naga Prasad, S.V., et al. 2002. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/betaarrestin complex. J. Cell Biol. 158:563-575.
46. Somers, V.K., Dyken, M.E., Clary, M.P., and Abboud, F.M. 1995. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 96:1897-1904.
47. Kraiczi, H., Caidahl, K., Samuelsson, A., Peker, Y., and Hedner, J. 2001. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest. 119:1085-1091.
48. Shahar, E., et al. 2001. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 163:19-25.
49. Harding, V.B., Jones, L.R., Lefkowitz, R.J., Koch, W.J., and Rockman, H.A. 2001. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. U. S. A. 98:5809-5814.
50. Ellmers, L.J., et al. 2002. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 283:H707-H714.
51. Knowles, J.W., et al. 2001. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. 107:975-984.
52. Nusz, D.J., et al. 2003. Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 285:H1554-H1562.
53. Dipla, K., Mattiello, J.A., Jeevanandam, V., Houser, S.R., and Margulies, K.B. 1998. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 97:2316-2322.
54. Naga Prasad, S.V., Barak, L.S., Rapacciuolo, A., Caron, M.G., and Rockman, H.A. 2001. Agonistdependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J. Biol. Chem. 276:18953-18959.